What Happened

Merck KGaA acquired Bio-Techne for $11.3 billion, its largest deal in over a decade, to strengthen its life sciences business. The offer of $73 per share represents a 24% premium over Bio-Techne's closing price.

Who Is Affected

The acquisition impacts scientists and drug developers who rely on Bio-Techne's research reagents, proteins, antibodies, and analytical instruments. Merck KGaA's life sciences division will also see significant growth.

Market Impact

• Merck expands its footprint in advanced biological research and cell and gene therapy.
• Bio-Techne's catalog of 6,000 proteins and 425,000 antibodies enhances Merck's offerings.
• The deal reinforces Merck's life sciences business as its primary growth driver.

What to Watch

Monitor the deal's expected closure by late 2026 or early 2027 and Merck's projected cost savings of 140 million euros by the third year post-closure. Watch for further acquisitions as Merck continues to prioritize life sciences investments.